Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Artiva Biotherapeutics (ARTV) Income from Continuing Operations (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Income from Continuing Operations for 3 consecutive years, with 20770000.0 as the latest value for Q4 2025.

  • For Q4 2025, Income from Continuing Operations fell 29.09% year-over-year to 20770000.0; the TTM value through Dec 2025 reached 83851000.0, down 35.39%, while the annual FY2025 figure was 83851000.0, 28.27% down from the prior year.
  • Income from Continuing Operations hit 20770000.0 in Q4 2025 for Artiva Biotherapeutics, up from 21525000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 13251000.0 in Q4 2023 and bottomed at 21525000.0 in Q3 2025.
  • Average Income from Continuing Operations over 3 years is 12056454.55, with a median of 16090000.0 recorded in 2024.
  • Year-over-year, Income from Continuing Operations crashed 246.84% in 2024 and then decreased 29.09% in 2025.
  • Artiva Biotherapeutics' Income from Continuing Operations stood at 13251000.0 in 2023, then crashed by 221.42% to 16090000.0 in 2024, then decreased by 29.09% to 20770000.0 in 2025.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 20770000.0, 21525000.0, and 21249000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.